AI-generated analysis. Always verify with the original filing.
Pasithea Therapeutics Corp. disclosed under Item 3.01 on February 20, 2026, a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. This indicates potential non-compliance with exchange listing requirements.
Event Type
Disclosure
Mandatory
Variant
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On February 20, 2026, Pasithea Therapeutics Corp. (the “Comp